Bris­tol My­ers touts PhI­II Op­di­vo win in urothe­lial car­ci­no­ma; Lim­i­nal Bio­Sciences goes pri­vate

Bris­tol My­ers Squibb said Tues­day that a sub-study of a Phase III tri­al test­ing Op­di­vo with cis­platin-based chemother­a­py, fol­lowed by Op­di­vo monother­a­py, met the pri­ma­ry end­points of over­all sur­vival and pro­gres­sion-free sur­vival.

The sub-study was in pa­tients with un­re­sectable or metasta­t­ic urothe­lial car­ci­no­ma as a first-line treat­ment, ran­dom­iz­ing 608 pa­tients to ei­ther re­ceive Op­di­vo with chemo every three weeks or chemother­a­py on­ly. Ef­fi­ca­cy mea­sures were met, and the com­pa­ny added that the com­bi­na­tion had a “tol­er­a­ble safe­ty pro­file.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER